

Becond Preferably the fusion partner is protein D or its' lipidated derivative Lipoprotein D, from Haemophilus influenzae B. In particular, it is preferred that the N-terminal

In the claims:

Please amend claims 32-38 and 54 as follows:

- Sub. C1*
32. An immunogenic composition which comprises a protein comprising
- (a) an HIV Tat protein or an immunogenic derivative linked to an HIV Nef protein or an immunogenic derivative thereof; or
 - (b) an HIV Nef protein or an immunogenic derivative linked to an HIV Tat protein or an immunogenic derivative thereof; or
 - (c) an HIV Nef protein or an immunogenic derivative linked to an HIV Tat protein or an immunogenic derivative thereof and a fusion partner,
- in admixture with a pharmaceutically acceptable excipient.
- B2*
33. A composition as claimed in claim 32, comprising a Tat-Nef fusion protein or an immunogenic derivative thereof.
34. A composition as claimed in claim 32, comprising a Nef-Tat fusion protein or an immunogenic derivative thereof.
35. A composition according to claim 32, wherein the derivative of the Tat protein is an immunogenic mutated Tat protein.
36. A composition according to claim 32, wherein the derivative of the Nef protein is an immunogenic mutated Nef protein.
37. A composition as claimed in claim 32, wherein the fusion partner is a lipoprotein or an immunogenic derivative thereof.
38. A composition as claimed in claim 37, wherein the lipoprotein is Haemophilus Influenza B protein D or an immunogenic derivative thereof.